Advertisement

Latest News

Targeting Positive Affect May Prevent Depression Relapse, With Marie-José van Tol, PhD

39 minutes ago

Preventive cognitive therapy may reduce relapse in recurrent depression by strengthening positive affect and addressing anhedonia, van Tol explained.

REZOLVE-AA: 52-Week Data Highlight Positive Alopecia Areata Outcomes with Rezpegaldesleukin

2 hours ago

Phase 2b data from the 16-week extension of REZOLVE-AA suggest rezpegaldesleukin leads to continued hair regrowth through 52 weeks.

Sustained 1-Year Efficacy Seen with Clascoterone for Androgenetic Alopecia, With Maria Hordinsky, MD

2 hours ago

This interview highlights positive 12-month phase 3 results on clascoterone 5% topical solution for mild-to-moderate androgenetic alopecia, or hair loss.

Phase 3 MIRANDA Trial Links Tozorakimab to Fewer COPD Exacerbations

2 hours ago

Phase 3 MIRANDA found tozorakimab reduced COPD exacerbations in former smokers despite inhaled maintenance therapy.

Phase 3 HIBISCUS: Etavopivat Cuts VOC Events, Improves Hemoglobin in SCD

3 hours ago

Etavopivat reduced VOC events by 27% and improved hemoglobin response in the phase 3 HIBISCUS trial in sickle cell disease.

Advertisement
Advertisement